Table 2.
Chemotherapy regimen | Respondents (n = 63) |
The most commonly used number of cycles (n, %) |
---|---|---|
Gemcitabine/cisplatin D1, 8 of 21-d cycle | 56 (89%) | 4 cycles (40, 63%) |
Gemcitabine/carboplatin | 23 (37%) | 4 cycles (14, 22%) |
Gemcitabine/cisplatin D1, 8, 15 of 28-d cycle | 20 (32%) | 3 cycles (12, 19%) |
MVAC | 18 (29%) | 3 cycles (12, 19%) |
Dose-dense MVAC | 12 (19%) | 4 cycles (10, 16%) |
Gemcitabine/single agent | 6 (10%) | 6 cycles (3, 5%) |
Other (carboplatin/paclitaxel) | 2 (4%) | 3 cycles (2, 3%) |